NOTICE

Onegene Biotechnology to present at Bio Japan(Yokohama, Oct. 12-14) on Multi-specific drug platform UniStac® and OGB21502, the first UniStac® based Tetra-specific drug for liver fibrosis and NASH. Our CEO Sungjin Park is invited to the special session, "The forefront of new modality therapeutics from Asia" being held on the 13th of Oct. He will talk about how multi-specific drug can become potential therapy for complex diseases like NASH, liver fibrosis and cancer.